Statins in primary prevention: is the enthusiasm justified?
作者信息
Chopra Arun K, Yadav Rakesh
机构信息
Cardiology, Fortis Escorts Hospital, Amritsar, 143001, Punjab, India.
Cardiology, Dept. of Cardiology AIIMS, Ansari Nagar, New Delhi-29, India.
出版信息
Indian Heart J. 2020 Jul-Aug;72(4):221-224. doi: 10.1016/j.ihj.2020.07.021. Epub 2020 Aug 7.
Abstract
摘要
相似文献
1
Statins in primary prevention: is the enthusiasm justified?他汀类药物用于一级预防：这种热情合理吗？
Indian Heart J. 2020 Jul-Aug;72(4):221-224. doi: 10.1016/j.ihj.2020.07.021. Epub 2020 Aug 7.
2
Statins for primary prevention of cardiovascular disease.他汀类药物用于心血管疾病的一级预防。
BMJ. 2014 May 27;348:g3491. doi: 10.1136/bmj.g3491.
3
Statins for primary prevention: problems with cardiovascular-risk estimation?他汀类药物用于一级预防：心血管风险评估存在的问题？
Nat Rev Cardiol. 2013 Sep;10(9):547. doi: 10.1038/nrcardio.2013.80-c2. Epub 2013 Jul 23.
4
Addendum: Statins for primary prevention of cardiovascular disease.附录：他汀类药物用于心血管疾病的一级预防
Med Lett Drugs Ther. 2016 Dec 5;58(1509):158.
5
Statins for primary prevention: identifying low-risk individuals.用于一级预防的他汀类药物：识别低风险个体。
Nat Rev Cardiol. 2013 Sep;10(9):547. doi: 10.1038/nrcardio.2013.80-c1. Epub 2013 Jul 23.
6
Primary prevention for cardiovascular diseases: can statins replace aspirin?心血管疾病的一级预防：他汀类药物能替代阿司匹林吗？
Med Princ Pract. 2011;20(6):584. doi: 10.1159/000330033. Epub 2011 Oct 4.
7
[Statins in primary prevention of cardiovascular disease].[他汀类药物在心血管疾病一级预防中的应用]
Rev Med Interne. 2018 Jan;39(1):42-49. doi: 10.1016/j.revmed.2017.08.002. Epub 2017 Aug 31.
8
Statins and all-cause mortality in high-risk primary prevention of patients with cardiovascular risk factors.他汀类药物与心血管危险因素患者高危一级预防中的全因死亡率
Arch Intern Med. 2010 Dec 13;170(22):2041; author reply 2043-4. doi: 10.1001/archinternmed.2010.455.
9
Statins for primary prevention in people with a 10% 10-year cardiovascular risk: too much medicine too soon?他汀类药物用于10年心血管疾病风险为10%人群的一级预防：用药过早、用药过多？
Br J Gen Pract. 2017 Jan;67(654):40-41. doi: 10.3399/bjgp17X688789.
10
Statins for Primary Prevention: The Debate Is Intense, but the Data Are Weak.他汀类药物用于一级预防：争论激烈，但数据薄弱。
JAMA Intern Med. 2017 Jan 1;177(1):21-23. doi: 10.1001/jamainternmed.2016.7585.
本文引用的文献
1
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.低密度脂蛋白导致动脉粥样硬化性心血管疾病：病理生理学、遗传学及治疗学见解：欧洲动脉粥样硬化学会共识小组的共识声明
Eur Heart J. 2020 Jun 21;41(24):2313-2330. doi: 10.1093/eurheartj/ehz962.
2
Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews.他汀类药物用于心血管疾病一级预防的系统评价概述。
BMJ Open. 2019 Apr 23;9(4):e023085. doi: 10.1136/bmjopen-2018-023085.
3
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2018 年美国心脏病学会/美国心脏协会/美国心血管血管造影和介入学会/美国预防、物理治疗和康复医师学会/美国糖尿病协会/美国老年学会/美国药学会/美国医师协会/美国生理学会/北美介入放射学会/美国国家脂质协会/美国临床内分泌医师协会胆固醇管理指南：美国心脏病学会/美国心脏协会临床实践指南工作组的报告。
Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10.
4
Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease.爱尔兰他汀类药物使用情况及其预测因素的横断面分析，重点关注心血管疾病的一级预防。
BMJ Open. 2018 Feb 8;8(2):e018524. doi: 10.1136/bmjopen-2017-018524.
5
A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017.对 2017 年欧洲动脉粥样硬化学会共识小组共识声明的批判性评价。
Pharmacology. 2018;101(3-4):184-218. doi: 10.1159/000486374. Epub 2018 Jan 19.
6
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.载脂蛋白 AI 模拟肽（Anacetrapib）在动脉粥样硬化性血管疾病患者中的作用。
N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28.
7
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.低密度脂蛋白导致动脉粥样硬化性心血管疾病。1. 来自遗传、流行病学和临床研究的证据。欧洲动脉粥样硬化学会共识小组的共识声明。
Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144.
8
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
9
Cholesterol paradox: a correlate does not a surrogate make.胆固醇悖论：相关因素并不等同于替代指标。
Evid Based Med. 2017 Mar;22(1):15-19. doi: 10.1136/ebmed-2016-110602. Epub 2016 Dec 20.
10
Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews.用于动脉粥样硬化性心血管疾病一级预防的药物：系统评价概述。
JAMA Cardiol. 2016 Jun 1;1(3):341-9. doi: 10.1001/jamacardio.2016.0218.
Zotero 插件